Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Sponsor: Medical College of Wisconsin
You may qualify if…
- ✓ Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
- ✓ Age ≥ 18 years
- ✓ Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
- ✓ At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
- ✓ 1 or more high risk factors:
- ✓ History of preeclampsia
- ✓ Type 1 or 2 diabetes
- ✓ Multifetal gestation?
You may not qualify if…
- ✕ Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
- ✕ Chronic hypertension, according to ACOG guidelines
- ✕ Known allergy or contraindication to nifedipine
- ✕ Inability or unwillingness to provide informed consent
- ✕ Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)
Where it's recruiting
Milwaukee
Source: ClinicalTrials.gov · NCT07185204 · last updated 2026-07-20